©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Apr 26, 2024; 12(12): 2056-2064
Published online Apr 26, 2024. doi: 10.12998/wjcc.v12.i12.2056
Published online Apr 26, 2024. doi: 10.12998/wjcc.v12.i12.2056
Systematic review and network meta-analysis of different non-steroidal anti-inflammatory drugs for juvenile idiopathic arthritis
Tao Zeng, Jian-Zhong Ye, Hui Qin, Qian-Qian Xu, College of Medicine, Jingchu University of Technology Jingmen, Jingmen 448000, Hubei Province, China
Author contributions: Zeng T and Ye JZ conceived and designed the study; Qin H searched and selected relevant studies; Xu QQ and Zeng T extracted and interpreted data; and all authors critically reviewed and approved the final manuscript.
Supported by the Science and Technology Plan Project of Jingmen Science and Technology Bureau , No. 2018YFZD025 .
Conflict-of-interest statement: The authors declare that they have no conflict of interest to disclose.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Corresponding author: Qian-Qian Xu, MD, Senior Statistician, College of Medicine, Jingchu University of Technology Jingmen, No. 33 Xiangshan Road, Jingmen 448000, Hubei Province, China. yanfenjiu19940211@163.com
Received: September 22, 2023
Peer-review started: September 22, 2023
First decision: December 15, 2023
Revised: January 23, 2024
Accepted: March 1, 2024
Article in press: March 1, 2024
Published online: April 26, 2024
Processing time: 206 Days and 16.3 Hours
Peer-review started: September 22, 2023
First decision: December 15, 2023
Revised: January 23, 2024
Accepted: March 1, 2024
Article in press: March 1, 2024
Published online: April 26, 2024
Processing time: 206 Days and 16.3 Hours
Core Tip
Core Tip: In summary, celecoxib (6 mg/kg bid) was found to be the most effective non-steroidal anti-inflammatory drug for treating juvenile idiopathic arthritis. Rofecoxib, piroxicam, and meloxicam may be safer options, but further research is needed to confirm these findings in larger trials with higher quality studies.